Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cohance Lifesciences's Revenue for the
three
months ended in Jun. 2026 was ₹4,223 Mil. Cohance Lifesciences's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹6,810 Mil.
Hence, Cohance Lifesciences's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.62.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cohance Lifesciences Receivables Turnover Related Terms
Cohance Lifesciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543064 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cohance Lifesciences (BOM:543064) has a Receivables Turnover of 0.62 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cohance Lifesciences and its competitors. According to the industry distribution chart, Cohance Lifesciences ranks #762 out of 948 companies in the Drug Manufacturers industry, placing it in the top 80.4%.
Is Cohance Lifesciences' Receivables Turnover too high?
Cohance Lifesciences' current Receivables Turnover is 0.62. The Drug Manufacturers industry median Receivables Turnover is 5.07. Cohance Lifesciences' value of 0.62 is 87.8% below this industry median. Based on the distribution chart, Cohance Lifesciences ranks #762 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cohance Lifesciences has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #762 out of 948 companies for Receivables Turnover. This places Cohance Lifesciences in the lower half of its industry. The industry median Receivables Turnover is 5.07. Cohance Lifesciences' value of 0.62 is 87.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cohance Lifesciences's current Receivables Turnover of 0.62 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current Receivables Turnover is 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹802.76, compared to a current price of ₹440.00 — trading 45.2% below its estimated fair value. The current Receivables Turnover is 0.62 and 87.8% below the Drug Manufacturers industry median of 5.07. Cohance Lifesciences' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Receivables Turnover is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹440.00 is trading 45.2% below its estimated GF Value™ of ₹802.76.
GuruFocus considers Cohance Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:543064:
Receivables Turnover: 0.62
GF Value™: ₹802.76 vs. price of ₹440.00 (45.2% below fair value)
Industry Position: 87.8% below the Drug Manufacturers median (#762 of 948)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
83GF Score
Get the complete analysis for BOM:543064
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
